The BioLineRx pipeline is generated by systematically identifying, validating and in-licensing therapeutic candidates with advantages over current therapies or which address unmet medical needs.
Over 2,000 compounds have already been systematically screened and evaluated, of which over forty commenced development.
Currently we have two clinical-stage therapeutic candidate and one compound which has been commercialized.
BL-8040 - Multiple cancer and hematology indications Phase 3
AGI-134 - Solid tumors Phase 1/2a